Antithrombin effects of native and recombinant hirudins

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Hirudin is a potent and selective inhibitor of thrombin, a key enzyme in blood coagulation.
• Recombinant hirudins are developed as therapeutic alternatives to native hirudin.
• Amino acid variations can influence the binding affinity and efficacy of hirudin variants.

Purpose of the Study:

• To compare the selectivity and thrombin affinity of three recombinant hirudin variants (Lys-47, Arg-47, Asn-47) with native hirudin.
• To investigate the functional consequences of amino acid substitutions at position 47 on hirudin's inhibitory activity.

Main Methods:

• Characterization of recombinant hirudin variants with specific amino acid substitutions at position 47.
• Enzyme inhibition assays to determine thrombin affinity and selectivity.
• Assessment of hirudin's effect on thrombin-induced coagulation and platelet aggregation.

Main Results:

• Native hirudin and recombinant hirudin Lys-47 showed comparable high affinity for thrombin.
• Recombinant hirudins Arg-47 and Asn-47 exhibited significantly lower affinity for thrombin.
• All hirudins demonstrated similar potency in inhibiting thrombin-induced coagulation, but differences in thrombin affinity were only apparent in the inhibition of thrombin-induced platelet aggregation.

Conclusions:

• Amino acid substitutions at position 47 of hirudin can modulate its affinity for thrombin.
• Recombinant hirudin Lys-47 retains high affinity for thrombin, similar to native hirudin.
• The inhibition of thrombin-induced platelet aggregation is a more sensitive assay for detecting subtle changes in hirudin-thrombin affinity.